Clinical trials: Advanced Malignant Tumor
Malignant Pleural Mesothelioma
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
The main objective of the trial is to document the efficacy of NGR-hTNF administered at low dose weekly in advanced Malignant Pleural Mesothelioma patients previously treated with a pemetrexed-based chemotherapy regimen.
- Trial name
- NCT01098266
- Testing
- NGR-hTNF plus Best Investigator's Choice (BIC)
- Where
- 49 sites in United States, Belgium and 10 more
- Volunteers
- 400 people
- Sponsor
- AGC Biologics S.p.A.
Relapsed Malignant Solid Neoplasm
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced malignancies will be done to assess AUR107 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.
- Trial name
- NCT05865002
- Testing
- AUR107
- Where
- 37 sites in India
- Volunteers
- 50 people
- Sponsor
- Aurigene Discovery Technologies Limited
Advanced Solid Tumors, Inoperable
Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study
The purpose of this study is to select targeted treatment based on ex vivo kinase activity inhibition profiles to targeted agents of tumor tissue from patients with advanced cancer for whom no standard treatment is available.
- Conditions
- Advanced Solid Tumors, Inoperable, Metastasis
- Trial name
- TSAP (NCT01190241)
- Testing
- desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib
- Where
- 2 sites in Netherlands
- Volunteers
- 45 people
- Sponsor
- Amsterdam UMC, location VUmc
Melanoma
A Study of HX008 for the Treatment of Patients With Malignant Melanoma
HX008 is a humanized monoclonal antibody targeting PD-1 on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
- Trial name
- NCT04749485
- Testing
- HX008
- Where
- 11 sites in China
- Volunteers
- 119 people
- Sponsor
- Taizhou Hanzhong biomedical co. LTD
Cancer
Safety and Tolerability of NCP-IL-22BP mRNA in Advanced Solid Tumors
This is a phase I, open-label, single-arm, single-center, dose-escalation study to evaluate the safety, tolerability, and preliminary anti-tumor activity of NCP-IL-22BP mRNA, a non-cationic peptide-delivered mRNA encoding…
- Trial name
- NCT07562815
- Testing
- 25 μg NCP-IL-22BP mRNA, 50 μg NCP-IL-22BP mRNA, 100 μg NCP-IL-22BP mRNA
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Advanced Solid Tumor, Mesothelioma, Malignant
SW-682 in Advanced Solid Tumors
This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway…
- Trial name
- NCT06251310
- Testing
- SW-682, Combination Therapy
- Where
- 8 sites in United States
- Volunteers
- 186 people
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Advanced Malignant Tumor
BAT7104 Injection in Patients With Advanced Malignant Tumors.
A multi-center, open phase Ia/Ib clinical study to evaluate the safety, tolerance, pharmacokinetics and preliminary clinical efficacy of BAT7104 injection in patients with advanced malignant tumors.
- Trial name
- NCT05767060
- Testing
- BAT7104 injection
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Bio-Thera Solutions
Metastatic Pancreatic Neuroendocrine Tumor
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
This is a phase I, open-label study to assess the safety and preliminary efficacy of Fulvestrant in combination with 177Lu-DOTATATE for advanced pNETs.
- Trial name
- NCT06663072
- Testing
- Fulvestrant, 177Lu-DOTATATE
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Chicago
Cervical
RT201(Tumor Antigen-specific Macrophage Tumor Vaccine)
This clinical study will include tumor patients in strict accordance with the inclusion and exclusion criteria set in this clinical study, and carry out tumor-specific antigen screening, HLA typing, blood sample collection, cell…
- Trial name
- NCT05930301
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Peihua Lu
Advanced/Metastatic Solid Tumors
Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic profiles, and preliminary efficacy of HLX97 ( KAT6A/B inhibitor) in patients with advanced/metastatic solid…
- Trial name
- NCT07480681
- Testing
- HLX97, Fulvestrant
- Volunteers
- 138 people
- Sponsor
- Shanghai Henlius Biotech
Solid Tumor, Microsatellite Stable Colorectal Cancer
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
To determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) or intravenously and when combined with pembrolizumab in patients with solid tumors (RIVAL-01).
- Conditions
- Solid Tumor, Microsatellite Stable Colorectal Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Cervical Cancer
- Trial name
- RAPTOR (NCT04301011)
- Testing
- TBio-6517, Pembrolizumab
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 27 people
- Sponsor
- Turnstone Biologics, Corp.
Solid Tumor
Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
This is a phase 1 study in which 2 to 72 patients with advanced cancer will receive oral doses of rigosertib, a new investigational (unapproved) anti-cancer drug.
- Trial name
- NCT01168011
- Testing
- rigosertib
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Traws Pharma, Inc.
Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma
Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer.
In this project, based on the information of advanced gastric/gastroesophageal junction cancer in evolution under immunotherapy combined with chemotherapy treatment, we will integrate multi-omics dynamic data to identify…
- Trial name
- NCT06642857
- Testing
- Peripheral blood, tougue coating, saliva, and feces
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Xiangdong Cheng
Liver Cancer, Lung Cancer
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion…
- Conditions
- Liver Cancer, Lung Cancer, Breast Cancer, Colo-rectal Cancer
- Trial name
- NCT04842812
- Testing
- TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Solid Tumor
Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid Tumors
This is an open-label, phase I study evaluating safety, tolerability, pharmacokinetics and efficacy of Surufatinib combined with the humanized anti-PD-1 antibody JS001 in patients with solid tumors.
- Trial name
- NCT03879057
- Testing
- Surufatinib/humanized anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Peking University
Advanced Cancer, Solid Tumor
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
The goal of this clinical research study is to learn about the safety and effects of BMS-986504 in combination with olaparib in patients with advanced solid tumors with MTAP loss.
- Trial name
- NCT07382544
- Testing
- MRTX1719, Olaparib
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumor, Metastatic Solid Tumor
A Study of KK2269 in Adult Participants With Solid Tumors
This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT06266299
- Testing
- KK2269, Docetaxel
- Where
- 32 sites in United States, Japan
- Volunteers
- 83 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Squamous Cell Carcinoma of External Auditory Canal, Locally Advanced Tumor
Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal
To evaluate the efficacy and safety of induction chemotherapy combined with tislelizumab as neoadjuvant therapy in patients with locally advanced squamous cell carcinoma of the external auditory canal; to explore the improvement…
- Trial name
- NCT07370337
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Malignant Solid Neoplasms
Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment
The MOST Plus study is a two-period phase II clinical trial, conducted in patients with all types of progressive solid tumors after at least 1 prior systemic treatment regimen for advanced disease (in the absence of a validated…
- Trial name
- MOST plus (NCT02029001)
- Testing
- Nilotinib (400 mg BID), Everolimus (10 mg QD), Sorafenib (400 mg BID)
- Where
- 7 sites in France
- Volunteers
- 900 people
- Sponsor
- Centre Leon Berard
Epithelial Tumor, Malignant, Neuroendocrine Tumors
Proton Boost for Locally Advanced HEAD AND NECK TUMORS
The aim of this research project is to test the local response and the acute toxicity (which can be observed within 90 days).
- Trial name
- NCT03183271
- Testing
- external beam proton radiation therapy.
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- CNAO National Center of Oncological Hadrontherapy
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.